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J. SENTERRE REPORT ON SMOKE FLAVOURINGS 
ADOPTED ON 25 JUNE 1993 
1. Foreword 
The EEC "framework" Directive on Flavourings (1) contains a category of flavourings entitled "Smoke 
Flavourings". It also stipulates that further appropriate provisions should be adopted to ensure the 
safety of flavourings used or intended for use in or on foodstuffs to impart odour and/or taste. 
In the preliminary opinion of the Scientific Committee for Food given at its 73rd meeting on 18 May 
1990 it was stated: 
"The Committee (also) noted the absence of inventories on smoke flavours. 
The Committee concluded that a safety evaluation of flavours should be performed and that an 
inventory of flavours in use together with information on usage would be needed for this 
purpose". 
As stated in its GUIDELINES FOR THE EVALUATION OF FLAVOURINGS FOR USE IN 
FOODSTUFFS: 1. CHEMICALLY DEFINED FLAVOURING SUBSTANCES (2) adopted at the 81st 
Plenary Meeting 9-10 December 1991, the Committee emphasises that before an additive is accepted 
for use in food it should have been subjected to an adequate toxicological evaluation. In that context 
the Committee intends among other tasks to address the issues of the evaluation of flavourings 
categorised as smoke flavourings. As the Directive does not cover the process of smoking only general 
technical aspects of it will be addressed in this report. 
In elaborating the present document the Committee has drawn extensively on the Council of Europe 
documents (3,4) and on the assessment of some smoke flavourings by JECFA (5). 
2. General considerations 
Smoking is next to drying and salting of food perhaps the oldest process for preserving and flavouring 
food. It has been probably in use since man knew fire for about 90 000 years and possibly longer. The 
original primary objective to preserve food is achieved by dehydration and by diminishing the 
number of surface bacteria through the action of certain components of the smoke and thus to enhance 
its keeping qualities. The secondary objectives of imparting desirable structural and sensory 
alterations such as smoke colour and smoke flavour to the final product serve to make the smoked food 
attractive to the consumer. Today smoking is primarily used for organoleptic purposes. 
Hard woods are commonly used in the traditional smoking process occasionally with added aromatic 
herbs, spices and twigs of certain plants. Food is then exposed directly or indirectly to the generated 
smoke. 
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Smoke flavour can be imparted to food also by the use of smoke flavourings with acceptable 
organoleptic properties and processed to eliminate undesirable components such as PAHs. These 
smoke flavourings are intended for direct use in or on food and are therefore regarded as food 
additives. 
3. Technological considerations 
Although not within the ambit of the Directive, it is considered useful to include a brief discussion of 
the process of smoking in this section. 
3.1 Smoking with freshly generated smoke from pyrolysed wood or moist wood chips 
In the direct conventional smoking of food the components of the smoke attach to the surface of the 
exposed food by chemical and physical processes, e.g. condensation, adsorption, adhesion. The 
deposited smoke components subsequently penetrate into the treated food to a variable depth, 
depending on the nature of the food. As a result the smoked food becomes contaminated, albeit in 
small amounts, with components of the smoke, such as polycyclic aromatic hydrocarbons (PAH), 
phenols and formaldehyde, which may be hazardous to health. As smoking is difficult to control and 
standardize, it is necessary to develop smoking techniques which optimise the desirable effects of 
smoking and avoid, as far as possible, any of its adverse effects. 
Commercial smoking processes use various types of smoke generators in which a controlled combustion 
of wood takes place. Wood is either pyrolysed yielding fumes which on oxidation form smoke, or 
moist wood chips are heated to generate smoke directly. Hard woods are commonly used in the 
traditional smoking process but it is essential that only specified, acceptable types of natural wood 
are used. The following table sets out some examples and is not meant to be exhaustive: 
List of examples of untreated wood, bark and twigs for the generation of smoke 
Acer negundo L. Maple tree 
Betula pendula Roth. White birch 
B. alba L. and B. verrucosa Ehrh. 
Betula pubescens Ehrh. European birch 
Carpinus betulus L. Hornbeam 
Carya ovata (Mill.) Koch Hickory 
Castanea sativa Mill. Chestnut tree 
Eucalyptus sp. Eucalyptus 
Fagus grandifolia Ehrh. Beech 
Fagus silvática L. Beech 
Fraxinus excelsior L. Common ash 
Juglans regia L. Walnut tree 
Malus pumila Mill. Apple 
Prosopis juliflora DC. Mesquite wood 
Prunus avium L. Cherry tree 
Quercus alba L. White oak 
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Quercus ilex L. Holm oak 
Ouercus robur L. Common red oak 
Rhamnus frángula L. Alder Buckthorn 
Robinia pseudoacacia Black locust 
Ulmus fulva Michx. Sweet elm 
Ulmus rubra Mühlenb. Elm 
Herbs and spices may also be added, as well as twigs of Juniper and twigs, needles and cones of Picea. 
To minimize the presence, particularly of PAHs, in traditionally smoked foods the direct contact of 
the food with smoke can be avoided by the introduction of indirect smoking processes. Other measures 
to reduce the transfer of toxic components to the food being smoked include the interposition of cooling 
traps, washing filters and spatial separation from the smoke source. Every one of these modifications 
can however affect adversely the organoleptic results. PAH production can be reduced by keeping the 
smoke generation temperatures below 400°C, by filtering off the particulates, by wrapping products in 
casings impermeable to PAH, and by reducing the duration of smoking if the surface/weight ratio is 
high. However the smoking time depends largely on the product to be treated and the flavour to be 
achieved. The introduction of smoke flavourings now permits the reduction of contamination with 
hazardous compounds and enables accurate control of flavour intensity in the final product. 
3.2 Smoke flavourings 
Smoke flavourings may be divided into the following three types: Smoke condensates, smoke flavours 
prepared by mixing chemically defined flavouring substances, and smoke flavouring preparations. 
The latter are based on smoke condensates or on smoke flavours prepared by mixing chemically 
defined flavouring substances with the addition of other substances. 
Smoke condensates are traditionally based on three ways of fixing smoke: 
Firstly, smoke is trapped in water or possibly other liquids, e.g. alcohol/water mixtures or oil. These 
condensates are usually further processed, e.g. fractionated by extraction. The aqueous smoke 
condensates, from which the tarry organic phase containing the PAHs has been removed, are the 
commercially most important products. 
Secondly, smoke may be condensed to yield whole smoke condensates. They are obtained as 
pyroligneous acid products by the dry distillation of certain hard woods at 200-900 °C in the absence 
of air or in the presence of limited air, or from steam distillation at 100-400 °C with or without 
pyrolysis. These whole smoke condensates may be further processed e.g. by dilution with water to 
separate off the tarry phase combined with adjustment of the phenolic content or by the fractionally 
distilling the tarry part and recombining the purified acid, phenolic and neutral fractions in various 
patented proportions. These types of products are however of little commercial interest. 
Reports of the Scientific Committee for Food (Thirty-fourth series) 25 JUNE 1993 SMOKE FLAVOURINGS 
Thirdly, smoke is condensed on solids, e.g. sugar, salt, maltodextrins, meat, or bacon rind, which may 
be subsequently extracted with certain solvents. 
Smoke condensates are complex mixtures of variable composition and contain different amounts of a 
spectrum of compounds, e.g. carboxylic acids, ketones, furfural derivatives, lactones, and phenols 
(7,8). The likely most hazardous constituents are the PAHs, the total amount of potentially harmful 
PAHs other than benzo(a)pyrene being 5 to 10 times the amount of benzo(a)pyrene found (6). 
Smoke condensates prepared from smoke trapped in liquids, usually water, are separated from the 
tarry phase. The aqueous phase is then usually purified by filtration through charcoal and 
concentrated by distillation for the preparation of smoke flavours. 
Smoke condensed on solids, e.g. sugar, salt, meat or bacon rind, may be used as such or extracted with 
alcohol, methanol or other solvents and then purified by charcoal filtration and concentrated by 
distillation. Those products are not widely used and are therefore of minor commercial importance. 
The final smoke flavour preparations are usually formulated by adsorption of the condensate on a 
carrier, or by spray drying, or by incorporation into solvents or emulsions. They are applied to the 
surface of or mixed into food products and are not normally incorporated into curing salt preparations. 
Smoke flavouring preparations may be incorporated into food usually at concentrations from 0.1% to 
1%. 
4. Toxicological considerations 
As previously pointed out, the process of smoking is difficult to standardize and to control. As it is not 
covered by the Directive, no specific toxicological considerations have been developed for the 
evaluation of the safety of the process of smoking. 
4.1 Contaminants 
It is essential that woods treated with paint or impregnated with tar or wood preservatives including 
pesticides, e.g. arsenicale, chlorinated phenols, must be excluded as raw materials for smoke 
generation. Herbs, spices and twigs of certain plants may, however, be added for special flavouring 
properties. 
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Furthermore, because smoke flavourings are intended to be added deliberately to the food, they must 
comply with the following maximum limits for contaminants : 
Benzo(a)pyrene 10 μg/kg condensate (solvent/water free) giving rise to less than 
0.03 μg/kg final foodstuff as consumed 
Benzo(a)anthracene 20 μg/kg condensate (solvent/water free) giving rise to less than 
0.06 μg/kg final foodstuff as consumed 
As 3mg/kg, Hg lmg/kg, Cd lmg/kg, Pb 10mg/kg smoke condensate. 
4.2 Principles of toxicological evaluation 
Smoke flavourings need to be evaluated as any other food additive. 
Smoke flavouring preparations, based on mixtures of chemically defined substances, require no further 
assessment of their safety, provided the individual components have been evaluated previously and 
accepted as flavouring substances for foodstuffs. However, any components, which have not been 
evaluated previously, require the usual establishment of their safety to health as flavouring 
substances prior to their use (see Guidelines for the safety evaluation of flavouring substances (2)). 
Because of the wide physical and chemical differences in the preparations used for imparting a 
smoke flavour to food, it is not possible to design a common approach to the safety assessment of smoke 
flavourings. However, the existing multitude of individualised smoke flavouring preparations is 
based on only a limited number of commercially available smoke condensates mainly of the aqueous 
type. 
The SCF considered, as did JECFA (5), that ADIs cannot be allocated to such a complex group of 
substances and that other ways of establishing their safety have to be chosen. Only some well 
specified aqueous condensates and one tarry extract of a smoke condensate, prepared from a specific 
wood, have been tested in standard toxicological studies and evaluated by JECFA as provisionally 
acceptable for use as a flavouring in foods otherwise traditionally treated by smoking. 
In the opinion of the SCF the toxicological evaluation should therefore concentrate on the safety of 
smoke condensates on a case by case basis. 
The maximum limits for 3,4-benzpyrene of 0.03 μg/kg foodstuff and 0.03 μg/kg beverage are set out 
in Council Directive 88/388/EEC (1). 
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The following technological information is a prerequisite for the safety evaluation of smoke 
flavourings: 
information on the production method of the smoke condensate, the further processing, and the 
final steps in the production of the flavouring preparation; 
approximate qualitative and quantitative composition of the smoke condensate as well as the 
concentration used and similar data on the final smoke flavouring preparation; 
information on the use levels and the kind of foods for which the smoke flavouring is intended; 
The core set of toxicological data on the smoke condensate or the individual derived smoke flavouring 
preparation should comprise: 
an in vitro mutagenicity test in a prokaryotic system; 
an in vitro gene mutation test in cultured mammalian cells; 
an in vitro test for chromosomal damage in cultured mammalian cells; 
a 90-day feeding study in laboratory animals. 
Additional toxicological data may be required for assessment of the safety of the smoke flavourings 
as necessary. Here a stepwise approach may be used, depending among other things on the potential 
intake and the results of the core set of toxicological data. 
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Reports of the Scientific Committee for Food (Thirty-fourth series) REPORT ON THE ESSENTIAL REQUIREMENTS 
FOR INFANT FORMULAE AND FOLLOW-ON FORMULAE 
OPINION EXPRESSED ON 17 SEPTEMBER 1993 
1. Terms of reference 
To review certain essential characteristics of infant formulae and follow-on formulae. 
2. Introduction 
In 1983 the Committee adopted an Opinion on the minimum characteristics which should be required 
for infant formulae and follow-up milks made from cow's milk proteins (1). A second Opinion, 
delivered in 1988, specified the requisite characteristics of soya-based formulae (2), but the first 
report has, so far, been subject only to ad hoc amendments concerning the minimum levels of vitamin D 
in such products and the list of nutrients which may be added to them (3, 4). 
The Annexes to the three first opinions referred to above make up the body of Commission Directive 
91/321/EEC of 14 May 1991 on infant formulae and follow-on formulae. 
The Commission must ensure that the existing Community legislation is updated whenever necessary. 
A request for a review was recently sent to the Commission and, accordingly, the Committee was 
asked to review the provisions of Directive 91/321/EEC likely to have an effect on public health, as 
it is nearly 10 years since the first report was adopted. The review will apply only to those fields in 
relation to which there is new information likely to alter the Committee's previous opinion. 
3. Essential requirements for infant formulae 
3.1 Proteins 
The protein requirement for growth has been directly related to nitrogen composition of human milk 
(1,2). The protein content is estimated to be about 1.2 g protein/100 ml (determined as Ν χ 6,38). 
However, the true protein content is more likely to be around 0.9 g/100 ml, but available protein is 
only in the region of 0.7 g/100 ml when account is taken of the limited availability of IgA, lactoferrin 
and lysozyme, which are stable at low pH and relatively resistant to digestion (5). 
Since 1983 a number of studies have suggested that there may be adverse effects associated with the 
ingestion of high levels of protein and that, if the intake of protein from formula is reduced to a level 
more similar to that in human milk, the infants grow well and thrive. Further, infants between 4 and 
6 months of age given a level of protein reduced from that in conventional formula (from 2 g/100 ml to 
1.3 - 1.8 g/100 ml) achieve satisfactory rates of growth (6). On the other hand a whole series of 
studies published after the preparation of the Community Directive did not confirm, in term infants, 
that products with alteration in the casein/whey protein ratio were superior to the products made 
from unmodified cows milk (7 -15). 
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Therefore, it is questionable whether different criteria for the essential composition of these two 
types of formulae should be maintained or not. 
The quality of a protein is determined by the pattern of amino acids in the protein relative to the 
pattern of amino acids required by the metabolic demand in the body. Classically protein quality has 
been perceived in relation to the requirements for essential amino acids, but the evidence is increasing 
that, in infancy especially, attention has to be given to satisfying the metabolic demand for 
conditionally essential amino acids also (16-18). Moreover both human and bovine milk contain casein 
and whey proteins, but in different proportions, and the protein constituent of each major class of 
proteins is different. The whey proteins in bovine milk differ particularly in function and composition 
from those in human milk. In addition human milk contains quantitatively small amounts of other 
proteins (enzymes, growth modulators, hormones) which may be of considerable functional 
significance (19-22). 
In the past the growth and nitrogen balance of a breast fed infant and the composition of human milk 
have been used as the reference. More recently the metabolic response was assessed, using 
quantitative and qualitative biochemical indices or markers : for example either fasting plasma 
concentrations of amino acids and urea or the post prandial response in the concentrations of plasma 
proteins with variable turnover times and functions have been measured, e.g. albumin, prealbumin, 
retinol binding protein, fibronectin, etc. 
The plasma concentration urea during the first six months of life in infants taking human milk (2-3 
mmol/1) is lower than in infants taking conventional formula (4-6 mmol/1) and the urinary excretion 
of urea for infants on human milk (81 mg/kg/d) is less than on conventional formula (140 mg/kg/d). 
When the protein content of the formula is reduced (1.8 g/100 kcal) the urea concentration in plasma 
decreases to levels similar to those in infants on human milk. An understanding of the kinetics of urea 
metabolism in infancy should include an appreciation of the rate at which urea nitrogen is salvaged 
by the colonic microflora for further metabolic interaction (18). The possibility that salvaged urea 
nitrogen might contribute in significant amounts to the availability of nonessential (and possibly 
essential) amino acids cannot be excluded at this time (16,18). 
The plasma concentration of an individual amino acid is the resultant of a number of factors which do 
not necessarily vary together and include the protein intake, protein quality, pattern of synthesis and 
degradation of endogenous proteins and the demand for specific metabolic pathways other than 
protein synthesis. For conventional formula in the fasted state the amino acid profiles differ greatly 
from those seen on human milk, and also vary with the relative proportions of whey/casein (casein : 
higher concentrations of tyrosine, phenylalanine, methionine ; whey : higher concentrations of 
threonine) (5, 7, 8, 14, 23). In any case neither casein or whey dominant formula gives a pattern of 
amino acids which is the same as human milk at any level of protein intake (9, 10, 12, 24). 
The differences in plasma amino acids postprandially are even more marked than in fasting, 
although the difference is less marked in term than in preterm infants (23). Whereas in the adult the 
liver exerts a significant modulating effect upon the pattern of amino acids measured in peripheral 
blood relative to the dietary intake, this modulating effect is not seen extensively in the infant. The 
result is that large variations in the amino acid pattern of proteins ingested are transferred almost 
directly to peripheral blood. 
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Thus there are large excursions in the circulating concentrations of most of the essential amino acids 
which suggest that the ability of the infant to handle the metabolic load adequately is exceeded and 
that the dietary intake of essential amino acids exceeds the combined capacity of the needs of the 
infants for tissue protein synthesis and the catabolic capability (25). Finally compared with the 
plasma protein concentrations seen with human milk, low protein formula give similar concentrations 
of albumin and prealbumin and not dissimilar to higher protein concentration formula. 
Under these conditions, the Committee considered that there is no evidence to justify having different 
minimal values for the protein content of formula which vary in the ratio of bovine whey to casein 
proteins. It is considered safe to have a minimum level of protein in formula made from bovine milk 
proteins of 1.8 g/100 kcal. For an equal energy value, the formula must contain an available quantity 
of each essential and semi-essential amino acid at least equal to that contained in the reference 
protein (breast milk, as defined in Annex V of the Directive), allowing methionine and cystine to be 
added together. 
3.2 Fats 
The Committee had proposed that minimum and maximum fat levels in infant formulae should be 
between 3.3 and 6.5 g/100 kcal. This range now appears rather too wide: fats are the main source of 
energy in mother's milk (some 40 to 55%) and if fat levels in infant formulae are to be considerably 
reduced (3.3 g/100 kcal accounts for only 30% of the energy content) this must be compensated by an 
increase in the protein and/or carbohydrate content. This would necessarily lead to a 
hyperosmolarity in the foodstuff and an increased renal osmotic charge which might exceed the 
infant's metabolic capacity. Furthermore, during the first six months of life, fats provide some 90% of 
the energy used for growth and it is known that fat synthesis from carbohydrates constitutes an 
energetic disadvantage. Fat synthesis from carbohydrates consumes about 25% of the energy which 
they provide, whereas the deposition of fat derived from fats present in the food consumes only about 
1% of the energy provided. The endogenous synthesis of fats produces only non-essential fatty acids, 
which may unfavourably alter the ratio of unsaturated to saturated fatty acids in the tissues (26). 
Accordingly, the Committee concluded that the fat content of infant formulae should amount to at 
least 40% of the energy content, which is equivalent to 1.05 g/100 kJ (4.4 g/100 kcal). 
The use of sesame seed oil and cotton seed oil in infant formulae and follow-on formulae should 
continue to be prohibited. Sesame seed oil can induce allergies to certain unsaponifiable ingredients 
(27) and cotton-seed oil may contain cyclopentenic fatty acids which may have negative effects on 
the desaturation of fatty acids (28). 
Animal experiment in the perinatal period reveal a number of untoward effects of trans fatty acids, 
including a disturbed conversion of precursor essential fatty acids into long-chain polyunsaturated 
metabolites and impairment of prenatal and postnatal growth. In human premature infants inverse 
correlations between the exposure to frans fatty acids and body weight as well as essential fatty acid 
conversion were observed (29), indicating the potential occurrence of similar and serious side effects in 
man as observed in animals. The Committee therefore considered that the trans fatty acid content of 
formulae should be as low as practically feasible. 
Reports of the Scientific Committee for Food (Thirty-fourth series) 11 17 SEPTEMBER 1993 ESSENTIAL REQUIREMENTS FOR INFANT FORMULAE AND FOLLOW-ON FORMULAE 
Accordingly, it decided to introduce a maximum level for trans and positionally isomeric fatty acids 
in place of the general ban on fats containing more than 8% of trans fatty acids as currently laid down 
in the Directive. Apart from partially hydrogenated fat, the major source for trans fatty acids in 
infant formulae is cow's milk fat which may contain about 2 to 5% of trans fatty acids. Cow's milk fat 
is only used in fat blends in European formulae and, since it does not exceed 80% of total fat, an upper 
limit of trans fatty acid content of 4% of total fat can be set without limiting the current use of cow's 
milk fat in formula. This latter value is also similar to the average trans fatty acid content in mature 
human milk in Europe (30). 
Even though human milk composition is variable, typical contents of human milk of women consuming 
European diets are 4.4-7.1% for lauric acid and 6.3-8.2% for myristic acid of total fatty acids . Clearly 
higher values are found in the milk of women consuming diets with a low fat and very high 
carbohydrate content, with the highest values reported from poor populations in rural Africa (31, 32). 
It is conceivable that even higher values of lauric and myristic acids might be found in human milk if 
lactating women consumed more extreme diets. High levels of lauric and myristic acids in infant 
formulae are undesirable because of their marked hypercholesterolemic effects that exceed those of 
all other saturated fatty acids (33, 34). These side effects are considered undesirable even in infancy. 
The available data do not exclude untoward effects of lauric and myristic acid on lipoprotein 
metabolism in formula fed infants. Since other studies have documented marked 
hypercholesterolemic effects of these fatty acids, a cautious approach is appropriate and high 
formula contents of lauric and myristic acids should be avoided. The Committee therefore considered 
that there was insufficient reason to alter its position in this regard. The maximum lauric and 
myristic acid contents in infant formulae should remain 15% each of the total fat content. 
Side effects of dietary erucic acid intake have been documented in numerous studies. High dietary 
intakes of erucic acid induce myocardial lipidosis and necrosis as well as structural and functional 
abnormalities of mitochondria in rats and monkeys. Dietary erucic acid accumulates in large amounts 
in the rat heart indicating its slow catabolism. In myocardial mitochondria erucic acid reduces ß-
oxidation, oxygen consumption and ATP production. High dietary erucic acid intakes are associated 
with reduced rates of weight gain in chicks and rats and reduced energy utilization in humans as well 
as with greater mortality in young rats exposed to cold stress (35-37). Young infants with their 
immature metabolism are often more susceptible to untoward side effects of substances than mature 
organisms, which may also be the case with respect to erucic acid toxicity. Animal studies suggested 
that the severity of myocardial lipidosis induced by erucic acid is more severe in newborn piglets 
than in weaned pigs but below 0.8% of total fatty acids no adverse effects have been detected in 
newborn piglets (38). Of interest with respect to infant feeding is also the observation that erucic 
acid, like nervonic acid, inhibits fatty acid elongation in human fibroblasts (39). High erucic content 
of infant formulae thus could impair the infants' ability to synthesize adequate amounts of the 
physiologically important long-chain polyunsaturated fatty acids from dietary essential fatty acids. 
In the absence of hard data on safe levels of erucic acid intake in human infants, the Committee 
considered it prudent that, for the present, contents in infant formulae should not exceed 1% of total 
fatty acids. The Committee intend to examine this further. 
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Human milk in Europe contains average linoleic acid levels between 6.9 and 16.4% of fatty acids, 
with a median of 11% (32). Much lower and higher values have been reported in women consuming 
various diets. No firm evidence has been published documenting harmful effects in infants consuming 
formulae with a level of up to 1900 mg linoleic acid/100 kcal, but also no studies were published that 
investigated closely enough the possibility of possible side effects such as enhanced peroxide 
formation and immunosuppression in infants fed formulae with very high linoleic acid contents. Side 
effects of high parenteral intakes of linoleic acid have been reported in newborn infants, including 
depression of biologically active linoleic and alpha-linolenic acid metabolites in plasma and tissues, 
alteration of prostaglandin metabolism and increased peroxidation (40, 41). Also, there is no evidence 
of any benefit of enteral intakes of linoleic acid higher than 1200 mg/100 kcal. Therefore, the 
Committee decided that the present upper limit for linoleic acid content in infant formulae (285 
mg/100 kJ) should be maintained. 
There is general agreement in the scientific community that both n-6 and n-3 fatty acids are essential 
nutrients that need to be supplied to the infant for adequate growth and development. Human infants 
require large amounts of both n-6 and n-3 polyunsaturated fatty acids for deposition in growing tissues, 
in particular in the brain and retina, and there is evidence that deficiency of n-3 fatty acids during 
early growth leads to functional impairment of neural tissues (42). In agreement with the report on 
Population Reference intakes for the Community (43), the minimum alpha-linolenic acid content in 
infant formulae should be set at 0.5% of energy (50 mg/100 kcal). In addition, a range for the 
linoleic/alpha-linolenic acid ratio of 5-15 should be set, because both fatty acids compete for the 
same metabolic pathway and extreme ratios may interfere with the synthesis of their long-chain 
metabolites (26). 
The essential fatty acids in structural lipids of neural and other tissues are primarily long-chain 
polyunsaturated fatty acids (LCP) with 20 and 22 carbon atoms, such as arachidonic (20:4 n-6) and 
docosahexaenoic (22:6 n-3) acids. Infants with low birth weights appear to be unable to synthesize 
sufficient amounts of LCP from the dietary precursors linoleic (18:2 n-6) and alphalinolenlc (18:3 n-3) 
and, therefore, require a dietary supply of LCP for optimal functional development (26). It is not yet 
known whether healthy infants born at term will also benefit from a dietary supply of preformed 
LCP. However, the Committee does not object to the possibility of adding them in infant formulae 
provided that the resulting content in n-3 and n-6 LCP is similar to that present in breast-milk in 
Europe (32). Therefore if preformed LCP are added the content of n-6 LCPs should not exceed 2 % and 
that of n-3 LCPs should not exceed 1 % of total fatty acid content ; in addition the eicosapentaenoic 
acid (20:5 n-3) content should not exceed that of docosahexaenoic acid. 
3.3 Carbohydrates 
It is a well-established fact that infants suffering from lesions of the intestinal mucosa absorb sucrose 
better than lactose (44, 45), even though saccharasa activity is reduced in these circumstances (46). 
Whereas lactase activity is the limiting factor for lactose, saccharase is not a limiting factor for 
sucrose absorption; what limits it is the transfer of glucose and fructose resulting from its hydrolysis 
(47). The Committee considered, however, that Directive 91/321/EEC relates only to formulae 
intended for healthy infants in the Community and that consequently it did not have to take account 
of pathological situations. Since there were no other data to justify amending the Directive in this 
respect, the Committee decided to maintain the provisions relating to the carbohydrate content of 
infant formulae. 
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3.4 Iron 
The acceptable maximum limits for iron in infant formulae are lower in Europe (0.36 mg/100 kJ, i.e. 1.5 
mg/100 kcal) as compared with North America. The important argument in the United States to 
enrich infant formulae with higher iron concentrations is to prevent iron deficiency in high risk 
populations. It has been reported that because of the participation in the "Special Supplemental 
Food Program for Women, Infants and Children (WIC)" in the United States the incidence of iron 
deficiency in such high risk populations has considerably decreased (48). Infants fed formulae in 
which the concentration of iron is approximately 12 mg/100 kcal rarely present iron deficiency 
anaemia in the first year of life (49). 
Although iron deficiency anaemia during the first year of life is observed in European countries, its 
prevalence is not a major public health problem. Additional food of good quality (meat, cereals, 
vegetables and fruits) are introduced in most European countries at 3-5 months of age (50) and the use 
of follow-on milks with a higher iron content (up to 2 mg/100 kcal) in the age period 6-12 months has 
been widely accepted. No long term studies are available comparing the effects on iron status of infant 
formulae enriched with different iron contents. Infants receiving milk formulae with 6 mg iron per 
litre (0.9 mg/100 kcal) up to 9 months with additional fruits and vegetables from 3 months and cereals 
(with 40 mg iron/kg) and meat from 5 to 6 months had satisfactory haematological parameters at the 
age of 9 months (51). 
There may be two disadvantages of iron excess in infant formulae : the possible interaction of iron 
with the absorption of trace elements and the possible increase of the predisposition to infections. 
Indeed there is evidence for an interaction between iron and manganese (52) and iron and copper (53). 
Several studies in the interaction between iron and zinc demonstrate conflicting results (54-56). On the 
other hand, it has been reported that infants fed iron-fortified formulae (5 mg/1) had high counts of 
E. coli and low counts of bifidobacteria in the faecal flora. Infants fed unfortified formula had an 
intestinal flora more comparable to breast milk (57). Studying the effect of iron supplementation to 
whey and casein based infant formulae, both the type of protein and iron content had an effect on 
faecal flora (58). No convincing evidence of an effect of iron fortification on the prevalence of 
infections has been shown. It would require a very large study population to demonstrate such an 
effect in a comparative study. 
In view of the possible interaction between iron absorption and the absorption of some trace elements, 
the possible effects of iron excess on the prevalence of infections and since there is no evidence that an 
iron content falling within the limits currently authorised results in a worse iron status, the 
Committee has decided that there is no reason to change the present day accepted limits for iron in 
infant formulae in Europe. 
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3.5 Trace elements 
Selenium (Se) is an element of the active site of glutathione peroxydase (GSH-Px), an enzyme which 
catalyses the reduction of hydroperoxydes resulting from the oxidative metabolism of 
polyunsaturated membrane phospholipids and xenobiotics (59). The deiodinase I enzyme responsible 
for triiodothyronine production is also a selenoenzyme and the deiodinases I and II are responsive to 
selenium intake (60). In humans, apart from cardiomyopathy of Keshan and chondrodystrophy of 
Kaschin-Beck described in endemically Se-deficient areas of China, clear evidence of selenium 
deficiency has been observed only in protein-energy malnutrition, long term total parenteral nutrition 
(TPN) and in certain inborn errors of metabolism (61). 
The selenium intake of breast-fed babies and infants receiving formulae based on cow's milk or soya 
protein, with a selenium content of more than 10-15 μg/l, is certainly enough to cover their 
requirements (61). In a number of European countries the selenium content of infant formulae is 
nonetheless under 10 μg/l, and even as low as 3-5 μg/l, meaning that the "minimum reference intake" 
of 4 to 6 μg/day (62) could be not covered (63). Therefore, where the selenium content would be 
naturally lower than 0.25 μg/100 kJ (1 μg/100 kcal), selenium may be added to infant formulae. 
Sodium selenate and selenite, selenomethionine or selenium enriched yeasts, provided that the 
selenomethionine concentration of these yeasts is well standardized, should be permissible to this 
effect. In order to maintain a sufficient margin of security, the maximum content of selenium, if added, 
should not exceed 0.7 μg/lΓJ0 kJ (3 μ^/ΙΟΟ kcal). 
Chromium (Cr) in its cationic trivalent form is a biologically active element essential for animal and 
human beings (64). Until recently, human milk was thought to contain between 40 and 80 μg of 
chromium per litre and it was generally accepted that cow's milk had a lower chromium content than 
human milk. Once the technical problems concerning measurement and sample contamination had 
been eliminated, it emerged that the real chromium concentration in human milk was on average of 
0.3-0.4 μg/l (65, 66). Consequently the estimated average chromium intake of breastfed infants does 
not exceed 0.3 μg/day (0.05 μg/kg). Since chromium was consistently found in high concentrations in 
human tissues during the first few weeks of life, it is highly unlikely that the chromium in mother's 
milk plays any significant role in the nutrition of young infants. Indeed no signs of chromium 
deficiency have been detected in young infants, except for glucose tolerance disorders responding to 
chromium supplementation in certain cases of protein-energy malnutrition (67). Although no recent 
data on the chromium content of infant formulae are available, there is nothing to suggest that 
chromium supplementation of such formulae is either necessary or desirable. 
Molybdenum (Mo) is one of the elements which make up various enzymes, including sulphite oxydase, 
which catalyse oxydation reduction reactions (68). The adequate and safe intake has been estimated 
at 0.5-1.5 μg/kg/day in infants, children and adolescents (62). Breast milk contains 1-2 μg/l at 1 
month lactation (69), whereas the molybdenum content of cow's milk is 30-70 μg/l (70). No clinical or 
biochemical anomaly which can be attributed to a molybdenum deficiency has so far been described in 
infants or children. Only hereditary deficiencies in sulphite oxydase enable us to affirm the essential 
role of molybdenum for the development of the foetus and the child (68). The Committee can thus find 
no justification for supplementing infant formulae or follow-on formulae with molybdenum. 
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3.6 Vitamins 
The new data which have become available regarding the young child's vitamin requirements do not 
justify amending Directive 91/321/EEC with regard to the essential composition criteria for infant 
formulae. It should be noted, however, that there was an error in the Committee report adopted in 
1983: the figures given for nicotinamide (60 μg/100 kJ or 250 μg/100 kcal) are the minimum values 
expressed in terms of nicotinamide and not in niacin equivalents (NE). They should therefore be 
replaced by 0.2 mg-NE/100kJ and 0.8 mg-NE/100kcal. 
4. Essential requirements for follow-on formulae 
4.1 Fats 
The provisions relating to the minimum and maximum fat content of follow-on formulae remain 
unchanged: the minimum value of 3.3 g/100 kcal is acceptable in the context of an already varied diet, 
even though ESPGAN recently expressed a preference for 4 g/100 kcal rather than the previously 
accepted figure of 3 g/100 kcal (71). 
The prohibition on the use of sesame seed oil and cotton seed oil is maintained (cf § 13). The same 
upper limit for trans fatty acid content as that proposed for infant formulae is suggested (cf § 14). The 
maximum lauric and myristic acid contents in follow-on formulae should remain 15% each of the total 
fat content (cf § 15). Moreover erucic acid content of follow-on formulae should not exceed 1% of total 
fatty acids (cf § 16). There is no change to the specifications relating to polyunsaturated fatty acids. 
4.2 Other composition criteria 
The provisions relating to the energy, protein, carbohydrate, mineral and vitamin contents given in 
Annex 11 to Directive 91/321/EEC remain unchanged. The Committee were concerned that the existing 
provision for the use of 20% of total carbohydrate as sucrose in follow-on infant formulae may 
contribute to dental caries in infants and young children. Therefore the Committee propose to examine 
this issue in the future. 
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5. Use of follow-on formulae 
In its report of 27 April 1983 the Committee had considered that follow-on formulae could be used by 
infants over the age of 4 months and young children. This position was in agreement with the 
recommendations of ESPGAN and is included in the relevant Codex Alimentarius Standard (CODEX 
STAN 156-1987). However, Directive 91/321/EEC restricts the term "follow-on foods'" to "foodstuffs 
intended for particular nutritional use by infants aged over four months". There is a legal vacuum 
therefore for the essential requirements of formulae intended specially for young children (aged 
between 1 and 3 years) and which are beginning to be marketed in some Member States. The use of 
follow-on formulae of inappropriate composition in this age group is of concern. If a formula is to be 
used by 1-3 year old children it should have the same composition as the follow-on formula made for 
infants. 
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22 Reports of the Scientific Committee for Food (Thirty-fourth series) OPINION ON MICROCRYSTALLINE CELLULOSE 
ADOPTED ON 17 SEPTEMBER 1993 
1. Terms of reference 
The Committee was asked to consider the safety in use of microcrystalline cellulose in relation to its 
particle size, particularly with respect to use in weaning and infant foods. 
2. Background and discussion 
Microcrystalline cellulose has been considered previously by the Scientific Committee for Food in its 
Fifth (1978), Seventh (1978) and Twenty-fourth (EUR 13140, 1991) Series of Reports. In the Fifth 
Series of Reports it was considered in the context of its use in fine bakers' wares and in the Seventh 
Series, in the broader context of its use in food in general. In both cases, the Committee endorsed the 
ADI "not specified" established by the Joint FAO/WHO Expert Committee on Food Additives 
(JECFA). In the case of its Seventh Series of Reports however, the Scientific Committee for Food 
noted that it wished to be informed of any further work elucidating the problem of persorption and 
indicated that it would re-assess the scientific evidence if any new findings became available. In its 
Twenty-fourth Series of Reports the Committee considered microcrystalline cellulose in the context of 
its use in weaning foods when it approved its use, in conjunction with other thickeners, at levels up to 
lg/100g in all weaning foods and at levels up to 2g/100g in gluten-free cereal-based foods. 
Microcrystalline cellulose is prepared by partial depolymerisation of alpha-cellulose with mineral 
acid. This process separates the hydrophilic and amorphous parts of the native cellulose molecule 
from the original starting material leaving material which is crystalline in nature. The article of 
commerce is then milled to give a product with a particle size appropriate for the intended use, in the 
case under consideration, as a food additive. The possibility exists that intact particles of 
microcrystalline cellulose may be persorbed across the wall of the gastro-intestinal tract with 
uncertain consequences for the health of consumers and this possibility may be increased where 
particles of small size are used. The Committee was asked to consider this question particularly in 
relation to weaning foods and infants foods because the permeability of the gastro-intestinal tract is 
known to be increased in babies and young children. The available toxicological studies with 
microcrystalline cellulose have been carried out only with materials having particle sizes in the 
range of 5 - 150 μηπ. Developments in milling technology and the demand for smaller particle sizes 
having improved suspension and "mouth feel" properties have led to the availability of materials 
with particle sizes as small as 0.15 μτη. 
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3. Conclusion 
With due regard to the increased intestinal permeability in infants and in older children and adults 
with compromised gut function, the Committee adopted the following opinion: 
microcrystalline cellulose of any particle size should not be permitted in any gluten-free foods 
specially prepared for infants and young children. In reaching this conclusion the Committee 
acknowledges and confirms that this represents a withdrawal of the acceptance previously given 
to this usage as recorded in its Twenty-fourth Series of Reports (EUR 13140, 1991); 
in the absence of toxicity data relevant to microcrystalline cellulose with a particle size less 
than 5 μιη, the Committee is unable to give any opinion on the safety in use of such material; 
to ensure that only microcrystalline cellulose for which adequate toxicity data exist be permitted 
for food use, a minimum particle size limit of 5 μπι should be introduced into the statutory 
specification; 
should approval for any food uses of microcrystalline cellulose with a particle size of less than 5 
μπι be requested, information should be provided on the lowest particle size required for the 
technological purpose intended; the foods in which such material would be used; the levels of use; 
and toxicity data to support the safety in use of material of the particle size in question; 
the Committee continues to be pre-occupied with the use of microcrystalline cellulose of particle 
size greater than 5 μιη in infant foods generally as well as in foods for individuals of any age 
suffering from increased gut permeability and will give this matter and its nutritional 
implications further consideration. 
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EXPRESSED ON 17 SEPTEMBER 1993 
1. Background and discussion 
The Committee was asked to review the acceptability of polyoxyethylene(20)sorbitan mono-oleate 
(polysorbate 80) because a recent ΝΤΡ study had raised the possibility that the substance was 
carcinogenic in F344/N rats. Polysorbate 80 has previously been evaluated by JECFA and the SCF. In 
1983 the SCF allocated to it, along with the polyoxyethylene sorbitan mono-esters of lauric and 
palmitic acids and the mono- and the tri-ester of stearic acid, a group ADI of 10 mg/kg bodyweight. 
In reviewing the data from the ΝΤΡ study, the Committee noted that the effect (an increased 
incidence of neoplastic and non-neoplastic lesions of the adrenal medulla, spleen and haemopoetic 
system) was seen in the high dose male rats but not in female rats nor in male and female B6C3Fj 
mice. Ames test results in four strains of S. typhimurium, with and without metabolic activation, 
were negative. Several mutagenicity studies carried out by other authors (gene mutations in bacterial 
cells, chromosome aberrations (CA) and sister chromatid exchanges (SCE) in cultured mammalian 
cells, CA and micronuclei in rodent bone marrow cells in vivo) had shown that polysorbate 80 is non-
genotoxic. 
2. Conclusion 
The data available are adequate to provide assurance of the absence of genotoxicity. The data on 
carcinogenicity are equivocal, effects being observed at high doses and in male rats only. Lesions of 
the type observed in the adrenal medullar, phaeochromocytomas, have also previously been 
associated with poorly metabolised food additives given to animals at high doses and have been 
regarded as of no significance for humans. In this instance the effects were seen at such high doses 
that there is an adequate safety margin between the no observed effect level and the present ADI. In 
the view of the Committee there are no grounds for requesting further studies nor for changing the 
existing acceptable status of polysorbate 80. 
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EXPRESSED ON 17 SEPTEMBER 1993 
1. Terms of reference 
To advise on the use of dimethylterephthalate (DMT) obtained by depolymerization of PET bottles 
already used in contact with drinks. 
2. Discussion 
The data submitted refer essentially to the regeneration of purified dimethylterephthalate (DMT) 
from scrap polyethylene terephthalate (PET) derived entirely from PET bottles used for drinks. 
The regeneration of DMT as described by Coca Cola International involves the thermal 
depolymerization of chopped PET scrap by glycolysis with ethylene glycol. The resulting 
intermediate mono (hydroxyethyl) terephthalate is converted to the bis (hydroxyethyl) 
terephthalate and then by ester exchange in the presence of methanol and a catalyst to DMT. This 
DMT is then purified by several steps including washing, recrystallization and vacuum-distillation 
and the pure material blended in a ratio of 1 + 3 with DMT produced by another industrial process 
from p-xylene. The blend is then repolymerised in the presence of ethylene glycol into PET resin, from 
which new PET bottles are produced by extrusion and stretch-blowing. 
The data supplied give chromatographic evidence of purity of DMT and analytical evidence of 
absence of any carry-over of 4 chemical contaminants. The absence of microbial contaminants or 
microbial metabolites is not shown by any test. 
From the toxicological point of view the starting monomer DMT is in the SCF list 2 (substances for 
which a TDI or a t-TDI has been established by this Committee) with a TDI of 1 mg/kg b.w., based on 
90-day oral mouse and rat studies and long-term studies in mice and rats which do not indicate any 
tumorigenic potential. 
3. Conclusion 
The Committee considered that there is no special requirement for dealing with DMT recovered from 
PET bottles already used in contact with drinks. It recalled that the criteria for approval of plastic 
materials were already set out in EC Directives and, for the special case of recovering monomers by 
depolymerization of finished plastic articles already used, in the Guidelines on the Community 
Positive Lists for Plastic (Practical Guide NI, CS/PM/2024 page 20, para 6). 
On the basis of the data presented the monomer complies with the above criteria. Therefore there is 
no reason why this DMT recovered from PET bottles already used in contact with drinks should not be 
used. It should be emphasized that the final responsibility for compliance of the plastic materials 
with EC Directives, including the absence of contaminants, still rests with the manufacturer. 
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ADOPTED ON 25 JUNE AND 10 DECEMBER 1993 
1. Background 
Chymosin (chymase, rennase or rennin) is the principal milk-clotting agent in rennet, which is 
commercially prepared by aqueous extraction of the dried fourth stomach of unweaned calves. Rennet 
has a long history of safe use in making cheese. The aqueous extract contains a chymosin precursor, 
prochymosin, which is subsequently converted to enzymatically active chymosin. Calf rennet contains 
different forms of chymosin, viz. A and Β at concentrations of ca. 22% and ca. 55% respectively 
(derived from prochymosin A and B), chymosin C2, which is a degradation product of chymosin A, 
and chymosin C, which is assumed to be a third genetic variety. In addition bovine rennet contains 
pepsin (ca. 15%). 
Biochemically, chymosin is a protein consisting of a single polypeptide chain of 323 amino acids with 
intramolecular disulfide linkages. Chymosin A and Β have been shown to differ only by one amino 
acid in the polypeptide chain. Chymosin A has an aspartic acid residue at position 286, whereas 
chymosin Β has a glycine residue at the same position. 
The Committee was informed that due to a decrease in the amount of calves slaughtered and an 
increase in cheese production there is a shortfall in the rennet required for cheesemaking. To 
compensate this shortfall, microbial cheese rennets produced as extracellular enzymes of fungi are 
available and, to widen the choice still further, recombinant calf rennets have been developed. 
Recombinant DNA technology has made it possible to obtain calf chymosin as a fermentation product 
from strains of bacteria, yeasts or filamentous fungi which have been transformed with a vector 
including a sequence of calf DNA coding for the chymosin precursor. 
After isolation and purification of preprochymosin mRNA from the fourth stomach of the calf, 
purified mRNA serves as a template for the synthesis of a complementary DNA strand (cDNA) using 
the enzyme reverse transcriptase. This cDNA is subsequently converted to double-stranded DNA with 
the use of DNA polymerase. The double stranded DNA is then ligated into an expression vector, 
which can be a plasmid or a virus, and the resultant recombinant DNA material is introduced into the 
host cells which serve as the source organism for enzyme production, using standard transformation 
techniques. 
The Committee was asked to evaluate chymosins obtained from three different microorganisms 
modified by recombinant DNA techniques: 
1. Chymosin A produced by Escherichia colt containing the bovine prochymosin A gene. 
2. Chymosin Β produced by Kluyveromyces lactis containing the bovine prochymosin Β gene. 
3. Chymosin Β produced by Aspergillus niger var. Awamori containing the bovine prochymosin B 
gene. 
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2. Toxicological evaluations and conclusions 
In its 27th series of reports (EUR 14181, 1992) the Committee set out the factors which it considered 
must be taken into account in the evaluation of enzyme preparations, including those obtained from 
genetically modified organisms. In evaluating the three chymosin products mentioned above, the 
Committee has applied the principles enunciated in its 27th series of reports. In accordance with 
these principles, the Committee draws particular attention to the fact that the evaluations which 
follow are confined to the products described in the dossiers submitted and cannot be considered to 
cover preparations of the same enzyme prepared from other sources or by other processes. 
2.1 Chymosin A produced by Escherichia coli K12 containing the calf prochymosin A 
gene 
The product evaluated by the Committee is derived from a genetically modified strain of Escherichia 
coli K12 GE81. The Committee was provided with information on the identity of the parent strain 
and the construction of the plasmid and method used to introduce the calf prochymosin A gene. 
Information was also provided to demonstrate that the modified organism is genetically stable. 
Intact plasmid is not detectable in the final product and acid treatment which is necessary for the 
purification procedure ensures that any residual DNA fragments present are smaller than 200 base-
pairs. 
Available toxicity data include the results of a 1-month oral gavage study in the rat, a 90-day 
feeding study in the rat and mutagenicity assays covering different genotoxic endpoints. In addition, a 
study in dogs and in vitro cytotoxicity assays showed no evidence of the production of any "shiga-
like" toxin that might have been potentiated by the modification of the E. Coli genome. The results 
of one passive cutaneous anaphylaxis study in guinea-pigs were equivocal but two further studies 
provide adequate assurance that allergenic potential is negligible. 
The Committee agreed that the use of the product is acceptable for use in the manufacture of cheese. 
12. Chymosin Β produced by Kluyveromyces lactis containing the calf prochymosin Β 
gene 
The product evaluated by the Committee is derived from a genetically modified strain of 
Kluyveromyces lactis (Dombrowski) van der Walt SL56. The Committee was provided with 
information on the parent strain and the construction of the plasmid and method used to introduce the 
calf prochymosin Β gene. Evidence indicating the genetic stability of the producing organism over 60 
generations was also provided. The use of an acid treatment to activate the enzyme extracellularly 
makes it unlikely that high molecular weight fragments of DNA will persist and no plasmid-
derived DNA was detectable in the final product. 
Available toxicity data include the results of an in vitro cytotoxicity test, acute toxicity and 28 and 
90-day studies in rats, a 90-day study in which rats were fed cheese prepared using the product, a 
passive cutaneous anaphylaxis assay in guinea-pigs and bacterial and mammallian cell mutagenicity 
assays. 
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In the 90-day rat study a slight but significant increase in relative liver weight was observed but this 
was not repeated in the 28-day study which was undertaken with special reference to hepatic 
function and histopathology. A slight increase in revertants was noted at high dose levels in some of 
the strains of Salmonella tested in the bacterial mutagenicity assays. No mutagenic activity was seen 
in several mammalian cell assays, neither in vitro nor in vivo. Judging the potential for genotoxicity 
on the entirety of the mutagenicity data, the Committee concluded that the positive reports were of 
no significance for the safety of the product. 
The Committee agreed that the use of this product is acceptable for use in the manufacture of cheese. 
2.3 Chymosin Β produced by Aspergillus niger var. Awamori containing the calf 
prochymosin B gene 
The product evaluated by the Committee is derived from a genetically modified strain of Aspergillus 
niger var. awamori designated GC1HF1-3, dgr246. The Committee was provided with information on 
the identity of the parent strain of A. Niger, the identity of the bacterial intermediate host which 
was the primary recipient of the calf prochymosin B gene and the construction of the plasmid which 
served as the means of transferring the calf gene to the final host. Information was also provided to 
demonstrate that the plasmid was integrated into the final host in a stable fashion and that neither 
plasmid-derived DNA nor RNA are detectable in the final product. 
Available toxicity data include the results of dermal and eye irritation studies in rabbits, a 50-day 
feeding study in rats, a sensitisation test in guinea-pigs and mutagenicity assays covering different 
genotoxic endpoints. In addition, the product was subjected to a cytotoxicity assay using cultured 
human lymphoblasts and live recombinant and host organisms were administered to mice by gavage 
with no evidence of toxicity. 
The Committee agreed that the use of this product is acceptable for use in the manufacture of cheese. 
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